Disseminated, persistent, and fatal infection due to the vaccine strain of varicella-zoster virus in an adult following stem cell transplantation

Clinical Infectious Diseases

Volumn 60, Issue 7, 2015, Pages 1068-1074

  Bhalla, Preeti ^a,d   Forrest, Graeme N ^a,b   Gershon, Michael ^c   Zhou, Yan ^c,e   Chen, Jason ^c   LaRussa, Philip ^c   Steinberg, Sharon ^c   Gershon, Anne A ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c College of Physicians and Surgns ^*  (United States)

^d Shanghai Jiaotong University ^*  (United States)

^e SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

granulomas; vaccine; varicella; vOka; zoster

Indexed keywords

ACICLOVIR; AMPHOTERICIN; CD20 ANTIGEN; CHICKENPOX VACCINE; FLUCONAZOLE; LIVE VACCINE; LIVER ENZYME; VALACICLOVIR;

ADULT; ADVERSE OUTCOME; ANTIVIRAL RESISTANCE; B CELL LYMPHOMA; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CASE REPORT; CHICKENPOX; COMPUTER ASSISTED TOMOGRAPHY; DRUG FATALITY; DRUG FEVER; FATIGUE; FEVER; HEPATITIS; HERPES ZOSTER; HUMAN; HUMAN TISSUE; IMMUNOCOMPROMISED PATIENT; IMMUNOCYTOCHEMISTRY; KIDNEY FAILURE; LARGE CELL LYMPHOMA; LIVER BIOPSY; LIVER GRANULOMA; LYMPHADENOPATHY; MALAISE; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; MYCOSIS; PANCYTOPENIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN BIOPSY; SKIN GRANULOMA; SKIN ULCER; STEM CELL TRANSPLANTATION; VACCINATION REACTION; VESICULAR RASH; VIRUS DETECTION; WEAKNESS; WEIGHT REDUCTION; ADVERSE EFFECTS; COMPLICATION; FATALITY; HERPESVIRIDAE INFECTIONS; ISOLATION AND PURIFICATION; LYMPHOMA, NON-HODGKIN; PATHOLOGY; VARICELLA ZOSTER VIRUS;

CHICKENPOX VACCINE; FATAL OUTCOME; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNOCOMPROMISED HOST; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; STEM CELL TRANSPLANTATION;

EID: 84926660927     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu970     Document Type: Review

References (40)

1. Gershon A, Takahashi M, Seward JF. Live attenuated varicella vaccine. In: Plotkin S, Orenstein W, Offit P, eds. Vaccines. 6th ed. Philadelphia: WB Saunders, 2013:837-69 .
2. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15: 1143-238.
3. LaRussa P, Lungu O, Hardy I, Gershon A, Steinberg S, Silverstein S. Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-Type varicella-zoster virus isolates. J Virol 1992; 66:1016-20.
4. Loparev VN, Argaw T, Krause PR, Takayama M, Schmid DS. Improved identification and differentiation of varicella-zoster virus (VZV) wild-Type strains and an attenuated varicella vaccine strain using a VZV open reading frame 62-based PCR. J Clin Microbiol 2000; 38:3156-60.
5. Parker SP, Quinlivan M, Taha Y, Breuer J. Genotyping of varicellazoster virus and the discrimination of Oka vaccine strains by TaqMan real-Time PCR. J Clin Microbiol 2006; 44:3911-4.
6. Gan L, Wang M, Chen JJ, Gershon MD, Gershon AA. Infected peripheral blood mononuclear cells transmit latent varicella zoster virus infection to the guinea pig enteric nervous system. J Neuroviro 2014; 20:442-56.
7. Sauerbrei A, Taut J, Zell R, Wutzler P. Resistance testing of clinical varicella-zoster virus strains. Antiviral Res 2011; 90:242-7.
8. Morfin F, Thouvenot D, De Turenne-Tessier M, Lina B, Aymard M, Ooka T. Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir. Antimicrob Agents Chemother 1999; 43:2412-6.
9. van der Beek MT, Vermont CL, Bredius RG, et al. Persistence and antiviral resistance of varicella zoster virus in hematological patients. Clin Infect Dis 2013; 56:335-43.
10. Sharrar RG, LaRussa P, Galea S, et al. The postmarketing safety profile of varicella vaccine. Vaccine 2000; 19:916-23.
11. Ghaffar F, Carrick K, Rogers BB, Margraf LR, Krisher K, Ramilo O. Disseminated infection with varicella-zoster virus vaccine strain presenting as hepatitis in a child with adenosine deaminase deficiency. Pediatr Infect Dis J 2000; 19:764-6.
12. Waters V, Peterson KS, LaRussa P. Live viral vaccines in a DiGeorge syndrome patient. Arch Dis Child 2007; 92:519-20.
13. Gershon AA, Gershon MD. Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin Microbiol Rev 2013; 26:728-43.
14. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T, Isomura S. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974; 2:1288-90.
15. Leung J, Siegel S, Jones JF, et al. Fatal varicella due to the vaccine-strain varicella-zoster virus. Hum Vaccin Immunother 2013; 10:46-9.
16. Kramer JM, LaRussa P, Tsai WC, et al. Disseminated vaccine strain varicella as the acquired immunodeficiency syndrome-defining illness in a previously undiagnosed child. Pediatrics 2001; 108:E39.
17. Jean-Philippe P, Freedman A, Chang MW, et al. Severe varicella caused by varicella-vaccine strain in a child with significant T-cell dysfunction. Pediatrics 2007; 120:e1345-9.
18. Schrauder A, Henke-Gendo C, Seidemann K, et al. Varicella vaccination in a child with acute lymphoblastic leukaemia. Lancet 2007; 369:1232.
19. Galea SA, Sweet A, Beninger P, et al. The safety profile of varicella vaccine: a 10-year review. J Infect Dis 2008; 197(suppl 2):S165-9.
20. Banovic T, Yanilla M, Simmons R, et al. Disseminated varicella infection caused by varicella vaccine strain in a child with low invariant natural killer T cells and diminished CD1d expression. J Infect Dis 2011; 204:1893-901.
21. Levy O, Orange JS, Hibberd P, et al. Disseminated varicella infection due to vaccine (Oka) strain varicella-zoster virus in a patient with a novel deficiency in natural killer cells. J Infect Dis 2003; 188:948-53.
22. Cohrs RJ, Gilden D. 2013 Colorado alphaherpesvirus latency symposium. J Neurovirol 2013; 19:610-7.
23. Gonzales JA, Levison AL, Stewart JM, Acharya NR, Margolis TP. Retinal necrosis following varicella-zoster vaccination. Arch Ophthalmol 2012; 130:1355-6.
24. Sabry A, Hauk PJ, Jing H, et al. Vaccine strain varicella-zoster virusinduced central nervous system vasculopathy as the presenting feature of DOCK8 deficiency. J Allergy Clin Immunol 2014; 133:1225-7.
25. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:309-18.
26. Veenstra J, van Praag RM, Krol A, et al. Complications of varicella zoster virus reactivation in HIV-infected homosexual men. AIDS 1996; 10:393-9.
27. Gershon A, Mervish N, LaRussa P, et al. Varicella-zoster virus infection in children with underlying HIV infection. J Infect Dis 1997; 176:1496-500.
28. Gesierich A, Krahl D, Weiss H, Brocker EB, Rose C. Granulomatous dermatitis following herpes zoster with detection of varicella zoster virus DNA. J Dtsch Dermatol Ges 2004; 2:770-2.
29. Gibney MD, Nahass GT, Leonardi CL. Cutaneous reactions following herpes zoster infections: report of three cases and a review of the literature. Br J Dermatol 1996; 134:504-9.
30. Gutzmer R, Kiehl P, Hausmann M, Kapp A, Weiss J. Post-zoster granuloma with detection of varicella zoster virus DNA in the granulomas. Hautarzt 2001; 52:1111-4.
31. Nikkels AF, Debrus S, Delvenne P, et al. Viral glycoproteins in herpesviridae granulomas. Am J Dermatopathol 1994; 16:588-92.
32. Requena L, Kutzner H, Escalonilla P, Ortiz S, Schaller J, Rohwedder A. Cutaneous reactions at sites of herpes zoster scars: an expanded spectrum. Br J Dermatol 1998; 138:161-8.
33. Sanli HE, Kocyigit P, Arica E, Kurtyuksel M, Heper AO, Ozcan M. Granuloma annulare on herpes zoster scars in a Hodgkin's disease patient following autologous peripheral stem cell transplantation. J Eur Acad Dermatol Venereol 2006; 20:314-7.
34. De Somer L, Wouters C, Morren MA, et al. Granulomatous skin lesions complicating Varicella infection in a patient with Rothmund-Thomson syndrome and immune deficiency: case report. Orphanet J Rare Dis 2010; 5:37.
35. Meyer B, Stalder H, Wegmann W. Persistent pulmonary granulomas after recovery from varicella pneumonia. Chest 1986; 89:457-9.
36. Yoshida I, Yoshino T, Takeuchi M. Elderly patient with varicella-zoster virus-Associated hemophagocytic syndrome refractory to steroid therapy. Rinsho Ketsueki 2005; 46:1229-32.
37. Takeoka Y, Hino M, Oiso N, et al. Virus-Associated hemophagocytic syndrome due to rubella virus and varicella-zoster virus dual infection in patient with adult idiopathic thrombocytopenic purpura. Ann Hematol 2001; 80:361-4.
38. McClain K, Gehrz R, Grierson H, Purtilo D, Filipovich A. Virus-Associated histiocytic proliferations in children. Frequent association with Epstein-Barr virus and congenital or acquired immunodeficiencies. Am J Pediatr Hematol Oncol 1988; 10:196-205.
39. Reiner AP, Spivak JL. Hematophagic histiocytosis. A report of 23 new patients and a review of the literature. Medicine (Baltimore) 1988; 67:369-88.
40. Quinlivan ML, Jensen NJ, Radford KW, Schmid DS. Novel genetic variation identified at fixed loci in ORF62 of the Oka varicella vaccine and in a case of vaccine-Associated herpes zoster. J Clin Microbiol 2012; 50:1583-8.